ImmuCell Corporation (ICCC) Return on equity 2017–2025
ImmuCell Corporation (ICCC) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-3.8%FY2025 · since FY2017: -0.7% → -3.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -3.8% | +4.0 pp |
| FY2024 | -7.8% | +15.3 pp |
| FY2023 | -23.1% | -14.9 pp |
| FY2022 | -8.2% | -8.0 pp |
| FY2021 | -0.2% | +3.4 pp |
| FY2020 | -3.6% | +0.9 pp |
| FY2019 | -4.5% | +6.2 pp |
| FY2018 | -10.7% | -10.0 pp |
| FY2017 | -0.7% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice